1784401-31-5

Upstream product

• 761460-02-0 tert-Butyl 3-(2-ethoxy-2-oxoethyl)morpholine-4-carboxylate 
• 761460-04-2 (3S)-4-tert-butoxycarbonyl-3-carbethoxymethylmorpholine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 81684-84-6 ethyl 2-(morpholin-3-yl)acetate 
• 86236-84-2 2-(morpholin-3-yl)acetic acid 
• 813433-72-6 (4-formyl-morpholin-3-yl)-acetic acid 
• 1000806-54-1 (E)-(4-tert-butoxycarbonylaminoethoxy)-2-butenal 
• 1257856-87-3 (R)-tert-butyl 3-(2-oxoethyl)morpholine-4-carboxylate 
• 859155-89-8 2-(4-(tert-butoxycarbonyl)morpholin-3-yl)acetic acid 

Relevant academic research and scientific papers

An efficient synthesis of chiral cyclic β-amino acids via asymmetric hydrogenation

Cyclic β-amino acids, homoproline, homopipecolic acid and 3-carboxy-methylmorpholine were obtained in high enantiomeric excesses by transition metal-catalyzed asymmetric hydrogenation of cyclic β-acylamino-alkenoates. These compounds were synthesized by a

NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME

Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R1 represents a hydrogen atom, an optionally substituted alkyl group, or the like; R2 represents a hydrogen atom, a halogen atom, or the like; and R3 represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions (by machine translation)

[Problem] imidazole compound or its pharmacologically acceptable salt in the melanocortin receptor activity that operates as an active ingredient of a pharmaceutical composition comprising. "I" general formula [a]" Formula, the aryl group may be substituted A ring represents a; R1 Represents a hydrogen atom, or an alkyl group which may be substituted represented; R2 Represents a hydrogen atom, a halogen atom or represents a; R3 The alkyl group may be substituted " represented by the imidazole compound, its pharmacologically acceptable salt as an active ingredient in a pharmaceutical composition. [Drawing] no (by machine translation)

N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurolo

Enantioselective organocatalytic intramolecular aza-Michael reaction: A concise synthesis of (+)-sedamine, (+)-allosedamine, and (+)-coniine

(Chemical Equation Presented) The intramolecular aza-Michael reaction of carbamates bearing remote α,β-unsaturated aldehydes under organocatalytic conditions took place with good yields and excellent ee's when Jorgensen catalyst IV was used in the process, giving rise to the enantioselective formation of several five- and six-membered heterocycles. The developed methodology was applied to the synthesis of three piperidine alkaloids.

Enzymatic resolution of cyclic N-Boc protected β-aminoacids

Methyl and ethyl esters of N-Boc homoproline, homopipecolic acid and 3-carboxymethyl-morpholine were kinetically resolved by hydrolysis catalysed by Burkholderia cepacia lipase to give the corresponding acids and residual esters in enantiomeric excesses better than 99% (E > 100).